文献速递肾癌与肾肿瘤

冯·希佩尔-林道病相关透明细胞肾细胞癌的纵向评估

Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease.
PubMed 文献 · Eur Urol · 2025-04-23

本研究为自然病史研究,纳入2004至2020年在美国国家癌症研究所评估和管理的244例VHL病患者(肾肿瘤≥10 mm),分析影像学结局、肾脏手术、转移、手术 sequalae(包括慢性肾病(CKD))和死亡。在至少三次连续肿瘤评估且随访至多5年的178例患者中,自发性肿瘤消退(≥30%缩小)率为1.8%(95%CI 0.4-5.2%),5年无疾病进展概率为37%(95%CI 30-44%)。结论认为RCC是VHL患者的重要负担,疾病进展、手术和转移发生率高,CKD是被低估的方面。

要点

  • VHL相关RCC患者5年无进展概率仅37%,疾病进展负担高。
  • 自发性肿瘤消退(≥30%缩小)率低,为1.8%。
  • 术后CKD发生率达41%,需重视肾功能保护。

核心结论

  • RCC是VHL患者的重要负担,即使在密切监测的多学科临床环境中,疾病进展、手术和转移发生率仍高。
  • CKD是VHL中未被充分认识的方面。

研究设计与样本

  • 自然病史研究,纳入2004至2020年在美国国家癌症研究所评估和管理的244例VHL病患者,肾肿瘤≥10 mm。

主要发现

  • 在178例至少三次连续肿瘤评估且随访至多5年的患者中,自发性肿瘤消退(≥30%缩小)率为1.8%(95%CI 0.4-5.2%)。
  • 存在竞争风险时,5年无疾病进展概率为37%(95%CI 30-44%)。
  • 随访期间,186/244例患者接受至少一次肾脏手术,108/244例接受至少两次。
  • 12例患者报告RCC转移。
  • 接受手术的患者中,41%发生术后CKD。

临床怎么用

  • VHL相关RCC患者需密切监测疾病进展,并关注术后CKD风险。
  • 研究结果可为新治疗方法的抗肿瘤活性评估提供背景参考。

局限性

  • 存在选择偏倚和结局错分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: An understanding the natural history of von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC) is critical to the development of optimal clinical management approaches and interpretation of trial results for comparable populations and endpoints. Our aim was to describe the natural progression of disease in patients with VHL RCC. METHODS: This was a natural history study involving 244 patients with VHL with ≥10-mm renal tumor(s) who were evaluated and managed at the US National Cancer Institute between 2004 and 2020. We analyzed radiographic outcomes, renal surgeries, metastasis, sequalae of surgery, including chronic kidney disease (CKD), and mortality. Radiographic outcomes were assessed according to Response Evaluation Criteria in Solid Tumours v1.1. The primary analyses were descriptive in nature. KEY FINDINGS AND LIMITATIONS: Among 178 patients with at least three serial tumor assessments and up to 5 yr of follow-up, the rate of spontaneous tumor regression (≥30% decrease) was 1.8% (95% confidence interval [CI] 0.4-5.2%). The probability of not having disease progression in the presence of competing risks at 5 yr was 37% (95% CI 30-44%). During follow-up, 186/244 patients had one or more renal surgeries, and 108/244 had two or more. RCC metastasis was reported for 12 patients. Among patients who underwent surgery, 41% developed postprocedure CKD. Potential limitations include selection bias and misclassification of outcomes. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study demonstrates that RCC is a significant burden for VHL patients, with high rates of disease progression, surgery, and metastasis development, even in a closely monitored, multidisciplinary clinical environment, and identifies CKD as an underappreciated aspect of VHL. These findings can provide a context for the antitumor activity of new treatments for RCC.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Linehan WM, Pinto CA, Liu Y, et al. Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease. Eur Urol. 2025. PMID: 40274483. doi:10.1016/j.eururo.2025.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。